Vera Therapeutics, Inc. (VERA)
NASDAQ: VERA · Real-Time Price · USD
42.60
+0.55 (1.31%)
Dec 20, 2024, 4:00 PM EST - Market closed
Company Description
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases.
Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.
It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections.
The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020.
Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Vera Therapeutics, Inc.
| Country | United States |
| Founded | 2016 |
| IPO Date | May 14, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 51 |
| CEO | Marshall Fordyce |
Contact Details
Address: 8000 Marina Boulevard, Suite 120 Brisbane, California 94005 United States | |
| Phone | 650 770 0077 |
| Website | veratx.com |
Stock Details
| Ticker Symbol | VERA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $11.00 |
| CIK Code | 0001831828 |
| CUSIP Number | 92337R101 |
| ISIN Number | US92337R1014 |
| Employer ID | 81-2744449 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Marshall W. Fordyce M.D. | Founder, President, Chief Executive Officer and Director |
| Sean P. Grant M.B.A. | Chief Financial Officer |
| David L. Johnson M.B.A. | Chief Opearating Officer |
| Joseph R. Young M.B.A. | Senior Vice President of Finance and Chief Accounting Officer |
| Dr. Allen Ebens B.Sc., Ph.D. | Executive Vice President of Research |
| Jason S Carter | Chief Legal Officer |
| Kelly Rauber | Senior Vice President of Human Resources |
| Tom Doan | Senior Vice President of Development Operations |
| Lauren Frenz M.B.A. | Chief Business Officer |
| Julien E. Capers J.D. | Senior Vice President of Legal |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 18, 2024 | 144 | Filing |
| Dec 11, 2024 | 144 | Filing |
| Nov 25, 2024 | 144 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | 144 | Filing |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |